#severeasthma — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #severeasthma, aggregated by home.social.
-
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
Sanofi’s SNY Dupixent, which it co-develops with Regeneron REGN, is its key top-line driver. The drug has transformed the treatment…
#France #FR #Europe #EU #Sanofi #approvedindications #atopicdermatitis #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #inflammatorydiseases #Regeneron #severeasthma #ZacksInvestmentResearch
https://www.europesays.com/france/40120/